Hisamitsu Pharmaceutical Co., Inc. (FRA:HPX)

Market Cap	2.32B +12.5%
Revenue (ttm)	879.51M +6.1%
Net Income	110.38M +28.6%
EPS	1.53 +32.7%
Shares Out	n/a
PE Ratio	20.98
Forward PE	n/a
Dividend	0.64 (1.99%)
Ex-Dividend Date	Aug 28, 2025

Volume	n/a
Average Volume	n/a
Open	32.00
Previous Close	33.00
Day's Range	32.00 - 32.00
52-Week Range	21.40 - 35.60
Beta	n/a
RSI	45.45
Earnings Date	Apr 9, 2026

About FRA:HPX

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete′s foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asi...

• Industry: Pharmaceutical Preparations
• Founded: 1847
• Employees: 2,799
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: HPX

Financial Performance

In fiscal year 2025, FRA:HPX's revenue was 156.01 billion, an increase of 10.09% compared to the previous year's 141.71 billion. Earnings were 21.76 billion, an increase of 55.76%.

Financial numbers in JPY